Over the past decades, the role of rearranged during transfection (RET) alterations in
tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic …

Cancer continues to be a major health concern globally, although the advent of targeted
therapy has revolutionized treatment options. Aurora Kinase B is a serine‐threonine kinase …

REarranged during Transfection (RET) is a validated target for anticancer drug discovery
and two selective RET inhibitors were approved by US FDA in 2020. However, acquired …

Rearranged during transfection kinase (RET) inhibition has been considered a promising
therapeutic approach for treatment of a variety of cancers. However, the clinical therapeutic …

Mesenchymal‐epithelial transition factor (c‐Met) is a tyrosine kinase receptor. Under certain
disease conditions, the cellular transformation process may be over‐activated, resulting in …

Aberrant RET kinase signaling is activated in numerous cancers including lung, thyroid,
breast, pancreatic, and prostate. Recent approvals of selective RET inhibitors, pralsetinib …

Over 120 small-molecule kinase inhibitors (SMKIs) have been approved worldwide for
treating various diseases, with nearly 70 FDA approvals specifically for cancer treatment …

Actionable mutations of RET kinase have been identified as oncogenic drivers of solid
tumors, including thyroid cancer, metastatic colorectal cancer, and nonsmall cell lung …

Since the oncogenic rearranged during transfection (RET) gene fusion was discovered in
non-small cell lung cancer (NSCLC) in 2012, multiple-targeted kinase inhibitors (MKIs) …

Cancer, caused by the failure of the mechanism that controls cell growth and proliferation, is
usually associated with severe health issues. Nowadays, chemotherapy still occupies an …